Associate Director, Congress Planning
Boost your chances before you apply.
Celcuity
US
Summary
The Associate Director leads the strategic planning, execution, and optimization of the company's congress program across various medical and commercial functions. This role oversees exhibit design, logistics, vendor management, and budget forecasting to ensure impactful stakeholder engagement and brand consistency.
Job Description
The Associate Director, Congress Planning is responsible for leading the strategic planning, execution, and continual optimization of Celcuity's congress program. This role serves as a key business partner across Marketing, Sales, Market Access, Medical Affairs and other cross-functional teams to deliver impactful congress experiences that enhance Celcuity's visibility, strengthen stakeholder engagement, and support corporate objectives. The Associate Director will oversee and execute the Celcuity congress program, including leading the overall planning process, project management, exhibit and event execution, agency management, budgeting, and operational excellence, while developing scalable processes and standards to support a growing portfolio of congresses.
Responsibilities:
Essential Job Functions and Responsibilities may include but are not limited to:
- Work cross functionally to develop a strategic framework for Celcuity’s congress/conference program from major Tier 1 conferences to sales led conferences, ensuring strategic alignment and brand consistency across the portfolio.
- Lead the overall strategic and tactical planning and execution of Tier 1 and Tier 2 medical congresses, including ASCO, ESMO, SABCS, JADPRO, ONS, and other key oncology congresses.
- Develop and implement congress plans that are aligned with commercial, medical, and corporate objectives and strategies.
- Serve as the primary congress lead and subject matter expert for internal stakeholders.
- Partner with Marketing, Sales, Medical Affairs and other cross-functional teams to define congress goals, priorities, and program requirements.
- Drive alignment, decision-making, and accountability across stakeholders throughout the planning process.
- Oversee exhibit/booth design, activation planning, and overall congress presence.
- Lead all congress logistics, including exhibit space, housing, meetings, events, and onsite operations.
- Ensure seamless onsite execution and proactively mitigate operational risks.
- Build and maintain relationships with professional societies, conference organizers, and industry partners.
- Identify opportunities to enhance Celcuity's visibility, engagement, and reputation at scientific meetings.
- Manage convention agencies and external vendors, ensuring high-quality service delivery and performance.
- Negotiate contracts and oversee vendor relationships to maximize value and mitigate risk.
- Develop and manage congress budgets, forecasts, and financial plans.
- Establish and maintain congress planning standards, processes, and SOPs.
- Provide guidance and support for sales-led conference activities, as appropriate.
- Measure congress performance and provide recommendations to optimize future investments and outcomes.
- Drive continuous improvement through process optimization, best practices, and lessons learned.
- Ensure all congress activities comply with company policies, industry regulations, and compliance requirements.
- Other duties as assigned.
Qualifications:
Required:
- Minimum 8+ years of relevant experience in biotech or pharmaceutical industry
- Demonstrated experience leading large-scale medical congresses and exhibit programs
- Knowledge of exhibit booth asset management for large, mid, and small portable
- Strong project management, budgeting and vendor management skills.
- Must have a good understanding of the pharmaceutical environment and demonstrate the ability to be proactive with respect to congress planning.
- Strong communication skills with a proven ability to influence and collaborate with cross-functional stakeholders.
- Exceptional organizational skills with the ability to manage multiple complex projects simultaneously.
- Willingness to travel and provide onsite leadership for congresses and events as required.
Preferred:
- Knowledge of oncology/breast congress landscape, US and ex-US
- Bachelor of Science/ Bachelor of Arts in a relevant discipline
- CTSM, HMCC
About Celcuity:
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.
The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.
Celcuity is an Equal-Opportunity Employer.
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $170,000 to $180,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.
Notice to Recruiters/Staffing Agencies
Recruiters and staffing agencies should not contact Celcuity through this page. All recruitment vendors (search firms, recruitment agencies, and staffing companies) are prohibited from contacting our hiring manager(s), executive team members, or employees directly.
We require that all recruiters and staffing agencies have a fully executed, formal written agreement on file. Celcuity’s receipt or acceptance of an unsolicited resume submitted by a vendor organization to this website or employee does not constitute an actual or implied contract between Celcuity and such organization and will be considered unsolicited. Celcuity will not be responsible for related fees.
Celcuity is a biotechnology company focused on developing and delivering targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK(TM)(gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- advanced breast cancer (ABC). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study were presented at ASCO 2026. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.
More detailed information about Celcuity’s active clinical trials is available at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis.
Founded
2012
Company size
51-200 employees
Industry
Biotechnology
Org type
Public Company
Headquarters
Minneapolis, MN
Celcuity is a biotechnology company focused on developing and delivering targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK(TM)(gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- advanced breast cancer (ABC). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study were presented at ASCO 2026. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.
More detailed information about Celcuity’s active clinical trials is available at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis.
Founded
2012
Company size
51-200 employees
Industry
Biotechnology
Org type
Public Company
Headquarters
Minneapolis, MN